Cited 0 times in
The role of sacubitril/valsartan in the management of cardiac resynchronization therapy non-responders: a retrospective analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강석민 | - |
dc.contributor.author | 김태훈 | - |
dc.contributor.author | 박희남 | - |
dc.contributor.author | 엄재선 | - |
dc.contributor.author | 오재원 | - |
dc.contributor.author | 유희태 | - |
dc.contributor.author | 이문형 | - |
dc.contributor.author | 이찬주 | - |
dc.contributor.author | 전경현 | - |
dc.contributor.author | 정보영 | - |
dc.date.accessioned | 2021-05-21T16:44:03Z | - |
dc.date.available | 2021-05-21T16:44:03Z | - |
dc.date.issued | 2020-12 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/182543 | - |
dc.description.abstract | Aims: Optimal medical therapy after cardiac resynchronization therapy (CRT) implantation is important in heart failure (HF) with reduced ejection fraction (HFrEF) patients. Although sacubitril/valsartan (SV) is a mainstay in the treatment of HFrEF, its efficacy in the management of CRT non-responders has not been emphasized. We aimed to investigate the efficacy of SV in CRT non-responders. Methods and results: We analysed 175 HFrEF patients who received CRT implantation between January 2010 and January 2019. CRT responder was defined as a decrease in left ventricular (LV) end-systolic volume > 15% on echocardiography 6 months after implantation. Medical records were retrospectively reviewed. Patients underwent follow-up for HF rehospitalization, heart transplantation (HT), implantation of a LV assistant device (LVAD), cardiac death, and all-cause death. Among the study population, 164 patients were evaluated for CRT response; 54 (33%) were CRT non-responders. Four patients (6%) who received SV before CRT implantation were excluded, leaving 50 patients for analysis. Twenty-two non-responders (44%) received SV. There was no significant difference in baseline characteristics between SV users and non-users (n = 28). During follow-up, SV users had significantly lower incidence of all-cause death [1 (5%) vs. 10 (36%), P = 0.022] and tended to have lower HF rehospitalization [6 (27%) vs. 16 (57%), P = 0.068] and cardiac death (including HT and LVAD implant) [2 (9%) vs. 10 (36%), P = 0.064]. Kaplan-Meier survival analysis revealed that SV use was associated with a lower risk of cardiac death (including HT and LVAD implant) (log-rank P = 0.029). Conclusions: SV treatment was related to a lower incidence of cardiac death including HT and LVAD implant in CRT non-responders. The optimization of HF management, including SV, should be considered in CRT non-responders. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | John Wiley & Sons | - |
dc.relation.isPartOf | ESC HEART FAILURE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | The role of sacubitril/valsartan in the management of cardiac resynchronization therapy non-responders: a retrospective analysis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Kyeong-Hyeon Chun | - |
dc.contributor.googleauthor | Jaewon Oh | - |
dc.contributor.googleauthor | Hee Tae Yu | - |
dc.contributor.googleauthor | Chan Joo Lee | - |
dc.contributor.googleauthor | Tae-Hoon Kim | - |
dc.contributor.googleauthor | Jae Sun Uhm | - |
dc.contributor.googleauthor | Hui-Nam Pak | - |
dc.contributor.googleauthor | Moon-Hyoung Lee | - |
dc.contributor.googleauthor | Boyoung Joung | - |
dc.contributor.googleauthor | Seok-Min Kang | - |
dc.identifier.doi | 10.1002/ehf2.12988 | - |
dc.contributor.localId | A00037 | - |
dc.contributor.localId | A01085 | - |
dc.contributor.localId | A01776 | - |
dc.contributor.localId | A02337 | - |
dc.contributor.localId | A02395 | - |
dc.contributor.localId | A02535 | - |
dc.contributor.localId | A02766 | - |
dc.contributor.localId | A03238 | - |
dc.contributor.localId | A03500 | - |
dc.contributor.localId | A03609 | - |
dc.relation.journalcode | J03871 | - |
dc.identifier.eissn | 2055-5822 | - |
dc.identifier.pmid | 32918402 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1002/ehf2.12988 | - |
dc.subject.keyword | Cardiac resynchronization therapy | - |
dc.subject.keyword | Heart failure with reduced ejection fraction | - |
dc.subject.keyword | Sacubitril/valsartan | - |
dc.contributor.alternativeName | Kang, Seok Min | - |
dc.contributor.affiliatedAuthor | 강석민 | - |
dc.contributor.affiliatedAuthor | 김태훈 | - |
dc.contributor.affiliatedAuthor | 박희남 | - |
dc.contributor.affiliatedAuthor | 엄재선 | - |
dc.contributor.affiliatedAuthor | 오재원 | - |
dc.contributor.affiliatedAuthor | 유희태 | - |
dc.contributor.affiliatedAuthor | 이문형 | - |
dc.contributor.affiliatedAuthor | 이찬주 | - |
dc.contributor.affiliatedAuthor | 전경현 | - |
dc.contributor.affiliatedAuthor | 정보영 | - |
dc.citation.volume | 7 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 4404 | - |
dc.citation.endPage | 4407 | - |
dc.identifier.bibliographicCitation | ESC HEART FAILURE, Vol.7(6) : 4404-4407, 2020-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.